UC researchers open Phase 2 clinical trial to test new combination treatment for glioblastomas

A multidisciplinary team of University of Cincinnati Cancer Center researchers have opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas (GBM), the most deadly form of brain tumors.

Related Keywords

Cincinnati ,Ohio ,United States ,Phoenix ,Arizona ,University Of Cincinnati ,American ,Lalanthica Yogendran ,Shesh Rai ,Rekha Chaudhary ,Pankaj Desai ,Biplab Dasgupta ,Gary Gudelsky ,Mario Medvedovic ,Catalyst Research Award ,Uc Jamesl Winkle College Of Pharmacy ,Falk Medical Research ,Clinical Cancer Research ,University Of Cincinnati Cancer Center ,Division Of Hematology Oncology ,Brain Tumor Center ,Marian Falk Medical Research ,American Association For Cancer Research ,Uc Brain Tumor Center ,Sciences Division ,Uc College Of Medicine ,Cincinnati Cancer Center ,Trisha Wise Draper ,Marian Falk Medical Research Trust ,Tumor Center ,Pharmaceutical Sciences Division ,American Association ,Medical Oncology ,Soma Sengupta ,Applied Science ,Cincinnati Children ,Walk Ahead ,Brain Tumor Discoveries ,Falk Catalyst Award ,Falk Medical Research Trust ,National Institutes ,National Institute ,Neurological Disorders ,David Plas ,Tim Phoenix ,Brain ,Brain Tumor ,Dancer ,Humor ,Flood ,Breast Cancer ,Catalyst ,Chemotherapy ,Clinical Trial ,Drugs ,Nzyme ,Medical Research ,Medicine ,Neuro Oncology ,Ncology ,Pharmacodynamics ,Pharmacy ,Reclinical ,Research ,Surgery ,